Gene Mutation Analysis Using Next-generation Sequencing and Its Clinical Significance in Patients with Myeloid Neoplasm: A Multi-center Study from China

Overview

Journal Cancer Med

Specialty Oncology

Date 2023 Feb 17

PMID 36799265

Authors

Junnan Li

Li Pei

Simin Liang

Shuangnian Xu

Yi Wang

Xiao Wang

Yi Liao

Qian Zhan

Wei Cheng

Zesong Yang

Xiaoqiong Tang

Hongbin Zhang

Qing Xiao

Jianbin Chen

Lin Liu

Li Wang

Affiliations

Soon will be listed here.

Abstract

Background: Myeloid neoplasms (MN) tend to relapse and deteriorate. Exploring the genomic mutation landscape of MN using next-generation sequencing (NGS) is a great measure to clarify the mechanism of oncogenesis and progression of MN.

Methods: This multicenter retrospective study investigated 303 patients with MN using NGS from 2019 to 2021. The characteristics of the mutation landscape in the MN subgroups and the clinical value of gene variants were analyzed.

Results: At least one mutation was detected in 88.11% of the patients (267/303). TET2 was the most common mutation in the cohort, followed by GATA2, ASXL1, FLT3, DNMT3A, and TP53. Among patients with myeloid leukemia (ML), multivariate analysis showed that patients aged ≥60 years had lower overall survival (OS, p = 0.004). Further analysis showed TET2, NPM1, SRSF2, and IDH1 gene mutations, and epigenetic genes (p < 0.050) presented significantly higher frequency in older patients. In patients with myelodysplastic syndrome (MDS) and myelodysplastic neoplasms (MPN), univariate analysis showed that BCORL1 had a significant impact on OS (p = 0.040); however, in multivariate analysis, there were no factors significantly associated with OS. Differential analysis of genetic mutations showed FLT3, TP53, MUC16, SRSF2, and KDM5A mutated more frequently (p < 0.050) in secondary acute myeloid leukemia (s-AML) than in MDS and MPN. TP53, U2AF1, SRSF2, and KDM5A were mutated more frequently (p < 0.050) in s-AML than in primary AML. KDM5A was observed to be restricted to patients with s-AML in this study, and only co-occurred with MUC16 and TP53 (2/2, 100%). Another mutation was MUC16, and its co-occurrence pattern differed between s-AML and AML. MUC16 mutations co-occurred with KDM5A and TP53 in 66.7% (2/3) of patients with s-AML and co-occurred with CEBPA in 100% (4/4) of patients with AML.

Conclusions: Our results demonstrate different genomic mutation patterns in the MN subgroups and highlight the clinical value of genetic variants.

Citing Articles

Prognostic impact of mutations on acute myeloid leukemia.

Tao Q, Wu Q, Xue Y, Chen C, Zhou Y, Shao R Ther Adv Hematol. 2024; 15:20406207241279533.

PMID: 39346679 PMC: 11439168. DOI: 10.1177/20406207241279533.

Prognostic significance of GATA2 in patients with MDS/AML: a systematic review and meta-analysis.

Han X, Liu W, Kang Z, Li D Ann Hematol. 2024; 103(12):4943-4952.

PMID: 39026028 DOI: 10.1007/s00277-024-05899-2.

Establishment and validation of a gene mutation-based risk model for predicting prognosis and therapy response in acute myeloid leukemia.

Liu Y, Li T, Zhang H, Wang L, Cao R, Zhang J Heliyon. 2024; 10(10):e31249.

PMID: 38831838 PMC: 11145431. DOI: 10.1016/j.heliyon.2024.e31249.

mutant variant allele frequency may reflect prognosis in Chinese adult patients with de novo cytogenetically normal acute myeloid leukemia.

Ren H, Hong M, Feng J, Hao Z, Chen X, Liang F Biomol Biomed. 2024; 24(4):982-989.

PMID: 38416121 PMC: 11293240. DOI: 10.17305/bb.2024.10244.

Gene mutation analysis using next-generation sequencing and its clinical significance in patients with myeloid neoplasm: A multi-center study from China.

Li J, Pei L, Liang S, Xu S, Wang Y, Wang X Cancer Med. 2023; 12(8):9332-9350.

PMID: 36799265 PMC: 10166913. DOI: 10.1002/cam4.5690.

References

Schneider J, Shen X, Orlandi C, Nyanhete T, Sawant S, Carias A . A MUC16 IgG Binding Activity Selects for a Restricted Subset of IgG Enriched for Certain Simian Immunodeficiency Virus Epitope Specificities. J Virol. 2019; 94(5). PMC: 7022352. DOI: 10.1128/JVI.01246-19. View

Tey S, Lane S . Better the cure you know: why patients with AML ≥60 years of age should be offered early allogeneic stem cell transplantation. Blood Adv. 2021; 6(5):1619-1622. PMC: 8905700. DOI: 10.1182/bloodadvances.2021004829. View

Carbonell D, Suarez-Gonzalez J, Chicano M, Andres-Zayas C, Trivino J, Rodriguez-Macias G . Next-Generation Sequencing Improves Diagnosis, Prognosis and Clinical Management of Myeloid Neoplasms. Cancers (Basel). 2019; 11(9). PMC: 6770229. DOI: 10.3390/cancers11091364. View

Hou H, Tsai C, Lin C, Chou W, Kuo Y, Liu C . Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome. Blood Cancer J. 2018; 8(4):39. PMC: 5884776. DOI: 10.1038/s41408-018-0074-7. View

Li L, An L, Chu X, Liu X, Wang L . [Analysis of the Effect of TET2 Mutation and SNP on Clinical Characteristics and Prognosis of AML Patients]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020; 28(2):453-459. DOI: 10.19746/j.cnki.issn.1009-2137.2020.02.016. View

Li M, Datto M, Duncavage E, Kulkarni S, Lindeman N, Roy S . Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2016; 19(1):4-23. PMC: 5707196. DOI: 10.1016/j.jmoldx.2016.10.002. View

Yun S, Geyer S, Komrokji R, Al Ali N, Song J, Hussaini M . Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML). Leukemia. 2020; 35(4):1145-1155. PMC: 7854836. DOI: 10.1038/s41375-020-0997-4. View

Abuhadra N, Mukherjee S, Al-Issa K, Adema V, Hirsch C, Advani A . and mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes. Leuk Lymphoma. 2019; 60(6):1587-1590. PMC: 8694070. DOI: 10.1080/10428194.2018.1543885. View

Martignoles J, Delhommeau F, Hirsch P . Genetic Hierarchy of Acute Myeloid Leukemia: From Clonal Hematopoiesis to Molecular Residual Disease. Int J Mol Sci. 2018; 19(12). PMC: 6321602. DOI: 10.3390/ijms19123850. View

10.

Northrup V, Maybank A, Carson N, Rahmeh T . The Value of Next-Generation Sequencing in the Screening and Evaluation of Hematologic Neoplasms in Clinical Practice. Am J Clin Pathol. 2019; 153(5):639-645. DOI: 10.1093/ajcp/aqz203. View

11.

Shokri G, Doudi S, Fathi-Roudsari M, Kouhkan F, Sanati M . Targeting histone demethylases KDM5A and KDM5B in AML cancer cells: A comparative view. Leuk Res. 2018; 68:105-111. DOI: 10.1016/j.leukres.2018.02.003. View

12.

Levis M, Perl A, Altman J, Gocke C, Bahceci E, Hill J . A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with -ITD mutations. Blood Adv. 2018; 2(8):825-831. PMC: 5916006. DOI: 10.1182/bloodadvances.2018015925. View

13.

Pollyea D, Bixby D, Perl A, Bhatt V, Altman J, Appelbaum F . NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. J Natl Compr Canc Netw. 2021; 19(1):16-27. DOI: 10.6004/jnccn.2021.0002. View

14.

Arber D, Orazi A, Hasserjian R, Borowitz M, Calvo K, Kvasnicka H . International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022; 140(11):1200-1228. PMC: 9479031. DOI: 10.1182/blood.2022015850. View

15.

Dohner H, Wei A, Appelbaum F, Craddock C, DiNardo C, Dombret H . Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022; 140(12):1345-1377. DOI: 10.1182/blood.2022016867. View

16.

Faust J, Hamill D, Kolb E, Gopalakrishnapillai A, Barwe S . Mesothelin: An Immunotherapeutic Target beyond Solid Tumors. Cancers (Basel). 2022; 14(6). PMC: 8946840. DOI: 10.3390/cancers14061550. View

17.

Heuser M, Freeman S, Ossenkoppele G, Buccisano F, Hourigan C, Ngai L . 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021; 138(26):2753-2767. PMC: 8718623. DOI: 10.1182/blood.2021013626. View

18.

Yu J, Li Y, Li T, Li Y, Xing H, Sun H . Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia. Exp Hematol Oncol. 2020; 9:2. PMC: 6945703. DOI: 10.1186/s40164-019-0158-5. View

19.

Wang R, Chen C, Jing Y, Qin J, Li Y, Chen G . Characteristics and prognostic significance of genetic mutations in acute myeloid leukemia based on a targeted next-generation sequencing technique. Cancer Med. 2020; 9(22):8457-8467. PMC: 7666719. DOI: 10.1002/cam4.3467. View

20.

Zhang M, Yin J, He Q, Zhang F, Huang H, Wu B . Chinese and Europeans with acute myeloid leukemia have discordant mutation topographies. Leuk Res. 2018; 70:8-12. DOI: 10.1016/j.leukres.2018.04.009. View